| scholarly article | Q13442814 |
| P50 | author | Jens Juul Holst | Q28373106 |
| P2093 | author name string | Meier JJ | |
| Nauck MA | |||
| Deacon CF | |||
| Hücking K | |||
| Schmiegel WH | |||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 2497-2504 | |
| P577 | publication date | 2001-11-01 | |
| P1433 | published in | Diabetes | Q895262 |
| P1476 | title | Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes | |
| P478 | volume | 50 |
| Q34308071 | A low-glycemic index diet combined with exercise reduces insulin resistance, postprandial hyperinsulinemia, and glucose-dependent insulinotropic polypeptide responses in obese, prediabetic humans |
| Q50519730 | Association of incretin receptors genetic polymorphisms with type 2 diabetes mellitus in Egyptian patients. |
| Q37141727 | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus |
| Q35559137 | Bench-to-bedside review: The gut as an endocrine organ in the critically ill |
| Q44495085 | Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects |
| Q40657251 | Cell-specific expression of the glucose-dependent insulinotropic polypeptide gene functions through a GATA and an ISL-1 motif in a mouse neuroendocrine tumor cell line |
| Q45137027 | Characterization of beta-cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests |
| Q37825941 | Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin |
| Q45061585 | Coffee consumption, serum gamma-glutamyltransferase and risk of type II diabetes |
| Q37332348 | Coffee, tea, and incident type 2 diabetes: the Singapore Chinese Health Study |
| Q33803511 | Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans |
| Q30998308 | Development of a robust QSAR model to predict the affinity of pyrrolidine analogs for dipeptidyl peptidase IV (DPP- IV). |
| Q58572799 | Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1 |
| Q37385927 | Does long-term coffee intake reduce type 2 diabetes mellitus risk? |
| Q36325570 | Dominant-negative inhibition of glucose-dependent insulinotropic polypeptide impairs function of β cells in transgenic pigs |
| Q35843905 | Effects of High Glucose Levels and Glycated Serum on GIP Responsiveness in the Pancreatic Beta Cell Line HIT-T15. |
| Q28573769 | Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets |
| Q35545683 | Enhancing Incretin Action for the Treatment of Type 2 Diabetes |
| Q46226028 | Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes |
| Q37236300 | Functional assessment of pancreatic beta-cell area in humans |
| Q37809995 | GIP and bariatric surgery |
| Q43116132 | GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus |
| Q35604671 | Gastric inhibitory peptide controls adipose insulin sensitivity via activation of cAMP-response element-binding protein and p110β isoform of phosphatidylinositol 3-kinase |
| Q44452284 | Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia |
| Q44215026 | Gastric inhibitory polypeptide does not inhibit gastric emptying in humans |
| Q34758871 | Gastric inhibitory polypeptide: the neglected incretin revisited |
| Q29147442 | Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge |
| Q38262673 | Glucagon and type 2 diabetes: the return of the alpha cell. |
| Q37880234 | Glucagon antagonism as a potential therapeutic target in type 2 diabetes |
| Q46919674 | Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans |
| Q34635520 | Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives |
| Q34401791 | Glucagon-like peptide 1(GLP-1) in biology and pathology |
| Q40132400 | Glucose intolerance and reduced proliferation of pancreatic beta-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function |
| Q37403983 | Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). |
| Q54475659 | Glucose-dependent insulinotropic polypeptide induces cytokine expression, lipolysis, and insulin resistance in human adipocytes. |
| Q40666632 | Glucose-dependent insulinotropic polypeptide reduces fat-specific expression and activity of 11β-hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids |
| Q39221120 | Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans |
| Q39021924 | Gut: A key player in the pathogenesis of type 2 diabetes? |
| Q44813375 | Impact of cereal fibre on glucose-regulating factors |
| Q42831893 | Increased GIP signaling induces adipose inflammation via a HIF-1α-dependent pathway and impairs insulin sensitivity in mice |
| Q37921901 | Incretin effect: GLP-1, GIP, DPP4. |
| Q35106875 | Incretin responses to oral glucose load in Japanese non-obese healthy subjects |
| Q36560963 | Incretins and the development of type 2 diabetes |
| Q35669308 | Incretins, insulin secretion and Type 2 diabetes mellitus |
| Q42627337 | Incretins: clinical physiology and bariatric surgery--correlating the entero-endocrine system and a potentially anti-dysmetabolic procedure |
| Q33866576 | Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls |
| Q33803409 | Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? |
| Q46768262 | Joint association of coffee consumption and other factors to the risk of type 2 diabetes: a prospective study in Finland |
| Q37811410 | K-cells and Glucose-Dependent Insulinotropic Polypeptide in Health and Disease |
| Q36783856 | Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes |
| Q35123524 | Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes |
| Q46133074 | Metabolic consequences of a 50% partial pancreatectomy in humans |
| Q47235131 | Microbial Regulation of Glucose Metabolism and Insulin Resistance |
| Q48154437 | Neonatal milk supplementation in lambs has persistent effects on growth and metabolic function that differ by sex and gestational age. |
| Q37306767 | New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. |
| Q42078124 | New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins |
| Q38024321 | Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus |
| Q42105494 | RETRACTED: Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment |
| Q36693199 | Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus |
| Q40197810 | Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans |
| Q58167429 | Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance |
| Q45970525 | Resistant starch intake at breakfast affects postprandial responses in type 2 diabetics and enhances the glucose-dependent insulinotropic polypeptide--insulin relationship following a second meal. |
| Q46595558 | Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes. |
| Q44688781 | Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects |
| Q38071991 | Structural aspects of gut peptides with therapeutic potential for type 2 diabetes. |
| Q58448416 | Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects |
| Q90533544 | The Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity |
| Q60920688 | The Regulation of Peripheral Metabolism by Gut-Derived Hormones |
| Q26783535 | The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones |
| Q36187070 | The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management |
| Q44397776 | The reduction in hepatic insulin clearance after oral glucose is not mediated by gastric inhibitory polypeptide (GIP). |
| Q36182540 | The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes |
| Q35760288 | The role of incretin therapy at different stages of diabetes |
| Q34901533 | The role of incretins in glucose homeostasis and diabetes treatment |
| Q37864256 | The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review |
| Q34648201 | Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes |
| Q37093181 | Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets |
| Q38006504 | Update on incretin hormones |
| Q27300376 | Vaccination against GIP for the treatment of obesity |
| Q39828276 | WNT/beta-catenin increases the production of incretins by entero-endocrine cells. |
| Q37811421 | Wnt and Incretin Connections |
Search more.